FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.

INTRODUCTION AND AIM Ovarian carcinoma (OC) is a common cancer in the Western Countries, and an important cause of death in patients suffering with gynaecologic malignancies. The majority of patients present with advanced disease at the time of diagnosis. Treatment with debulking surgery followed by chemotherapy is the standard approach while chemotherapy is contemplated when surgery is not possible. A correct pre-operative staging is important to ensure a most appropriate management. Laparoscopy (LPS) is the standard diagnostic tool for the assessment of intraperitoneal infiltration but is invasive and requires general anaesthesia. FDG-PET/CT is increasingly used for staging different types of cancer, and the aim of this study is to assess the value of FDG-PET/CT in staging advanced OC and its sensitivity to detect lesions in different quadrants of the abdominal-pelvic area compared to laparoscopy. MATERIALS AND METHODS From September 2004 till April 2008, 40 patients with high suspicion of OC were referred to our hospital for diagnostic LPS to explore the possibility of optimal debulking surgery. Those who were not suitable for surgery were referred for chemotherapy. Before chemotherapy, the patients underwent an FDG-PET/CT scan. The findings in 9 quadrants of abdominal-pelvic area (total 360 quadrants) for PET/CT and LPS were recorded and compared. RESULTS In 14/360 areas (3.8%), surgical evaluation was not possible because of presence of adhesions, thus the number of areas explored by laparoscopy was 346. Tumour was found in 308 quadrants (38 quadrants free of disease). PET/CT was positive in all 40 patients with true negative results in 26/346 quadrants (7.5%), and true positives results in 243/346 quadrants (70.2%). False positive and negative PET/CT results were found in 12/346 and 65/346 quadrants, respectively. False positive PET/CT findings were evenly present in all quadrants. False negative PET/CT findings were present in 31/109 (28.4%) upper abdominal quadrants (epigastrium and diaphragmatic areas). Final analysis showed a sensitivity and specificity for PET/TC of 78.9 and 68.4% respectively with a positive predictive value of 95.3%. A significant difference was noted between mean SUVmax associated with lesions smaller or larger than 0.5 cm (p=0.006). CONCLUSION Our results suggest that PET/CT may prove a useful tool for pre-surgical staging of ovarian cancer with a sensitivity and specificity of 78 and 68%, respectively. However, it may be used in combination with laparoscopy for better results. PET/CT showed an adequate correlation between SUVmax values and laparoscopy findings of lesions>5mm, but a high rate of false negative results in lesions<5mm such as in carcinomatosis. PET/CT should be used carefully in early stage disease, with low risk of peritoneal infiltration, because of high rate of false positive results, to avoid unnecessary therapy procedures.

[1]  B J McNeil,et al.  Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.

[2]  L. Mortelmans,et al.  Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer , 2003, Gynecologic and Obstetric Investigation.

[3]  F. Fazio,et al.  Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology , 2007, Nuclear medicine communications.

[4]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[5]  P. Maisonneuve,et al.  Carcinoma of the ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  K. Ulm,et al.  The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV , 1998 .

[7]  S. Larson,et al.  Peritoneal carcinomatosis: role of (18)F-FDG PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[9]  Thomas Beyer,et al.  A combined PET/CT scanner: the path to true image fusion. , 2002, The British journal of radiology.

[10]  A. De Gaetano,et al.  A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy , 2008, Oncology.

[11]  A. Loft,et al.  The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. , 2007, Gynecologic oncology.

[12]  R. Scully Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[13]  H. Vesselle,et al.  FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  M. Castiglione,et al.  Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Eriko Tsukamoto,et al.  PET/CT today: System and its impact on cancer diagnosis , 2006, Annals of nuclear medicine.

[16]  C. Rossi,et al.  Distant metastases in ovarian carcinoma , 2002, International Journal of Gynecologic Cancer.

[17]  Jae Hoon Kim,et al.  Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. , 2010, Gynecologic oncology.

[18]  R. Rouzier,et al.  External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. , 2008, Gynecologic oncology.

[19]  P. Sugarbaker Management of peritoneal-surface malignancy: the surgeon’s role , 1999, Langenbeck's Archives of Surgery.

[20]  J. Monaghan,et al.  Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. , 2000, Gynecologic oncology.

[21]  C. Nanni,et al.  Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[22]  M. Bellomi,et al.  Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET/CT , 2010, Abdominal Imaging.

[23]  R. Zang,et al.  Epithelial ovarian cancer presenting initially with extraabdominal or intrahepatic metastases: a preliminary report of 25 cases and literature review. , 2000, American journal of clinical oncology.

[24]  W. Kuhn,et al.  Neoadjuvant chemotherapy in ovarian cancer , 2004, Expert review of anticancer therapy.

[25]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Hanaoka,et al.  PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients , 2006, International Journal of Clinical Oncology.

[27]  R. Wahl,et al.  Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.